|Budget Amount *help
¥27,430,000 (Direct Cost: ¥21,100,000、Indirect Cost: ¥6,330,000)
Fiscal Year 2014: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
Fiscal Year 2013: ¥7,150,000 (Direct Cost: ¥5,500,000、Indirect Cost: ¥1,650,000)
Fiscal Year 2012: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
Fiscal Year 2011: ¥11,180,000 (Direct Cost: ¥8,600,000、Indirect Cost: ¥2,580,000)
|Outline of Final Research Achievements
I performed association studies to identify novel genetic factors for narcolepsy. HLA-DQB1*03:02, HLA-DPB1*05:01 and low frequency CNVs in PARK2 gene region were found to be associated with narcolepsy. In addition, I found a significant association between essential hypersomnia and a SNP in CRAT gene region.
To assess the efficacy of oral l-carnitine for the treatment of narcolepsy, I performed a clinical trial administering L-carnitine (510 mg/day) to patients with narcolepsy. L-carnitine treatment significantly improved the total time for dozing off during the daytime compared with that of placebo-treated periods. This study suggests that oral L-carnitine can be effective in reducing excessive daytime sleepiness in narcolepsy patients.